N/A N=1,439 Epidemiology of Severe Peroperative Bleeding During Scheduled Surgery
Surgery · Blood Loss
Primary: Unanticipated Bleeding — 0; 100; 0 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=22 Surgicel Snow in Gynecological Surgery
Laparoscopic Hysterectomy
Primary: Change in Bleeding at Specified Time Intervals — 485.7; 199.1 seconds
Phase 2 N=242 Outcomes and Safety Trial Investigating Ecallantide's Effect on Reducing Surgical Blood Loss Volume in Subjects at High Risk of Bleeding Exposed to Cardio-pulmonary Bypass During Cardiac Surgery
Bloodloss · Surgical Procedures, Operative
Primary: Cumulative Volume of Packed Red Blood Cells Transfused — 1223.2; 623.5 mL — p=0.001
Phase 2 N=48 Does Continued Use of Clopidogrel Into Surgery Cause Increased Perioperative Bleeding?
Clopidogrel
Primary: Bleeding-related Re-hospitalization — 1; 1 participants
Phase 4 N=40 Effect of Tranexamic Acid on Postoperative Bleeding Following Sinus and Nasal Surgery
Chronic Sinusitis · Nasal Obstruction · Turbinate; Hypertrophy Mucous Membrane
Primary: Bleeding VAS - POD1 — 5.03; 4.82 score on a scale — p=0.8
N/A N=184 Platelet Inhibition and Bleeding in Patients Undergoing Emergent Cardiac Surgery
Bleeding
Primary: Calculated Blood Loss — 1996 milliters
Phase 3 N=721 A Study of Fibrocaps™ in Surgical Bleeding
Mild or Moderate Surgical Bleeding
Primary: Time to Hemostasis (TTH) for Participants Receiving Spinal Surgery — 1.0; 2.5 minutes — p=< 0.0001
N/A N=103 SURGICEL® Powder in Controlling Mild or Moderate Parenchymal or Soft Tissue Intraoperative Bleeding in Adult Subjects
Hemorrhage
Primary: Haemostatic Success at 5 Minutes — 90 Participants
N/A N=24 Coagulation Factor Changes Associated With Postpartum Hysterectomies
Obstetric Labor Complications · Hemorrhage · Complications; Cesarean Section
Primary: Fibrinogen Level at 2 Hours After Delivery — 186; 418 mg/dL — p=<0.05
N/A N=62 Phlebotomy to Prevent Blood Loss in Major Hepatic Resections
Liver Neoplasms · Hepatectomy
Primary: Total Intraoperative Blood Loss, by Measurement of Change in Hemoglobin Levels — 862; 872; 761; 872 mL
Phase 2 N=295 Minimization of Bleeding Related Adverse Drug Events in Plastic & Reconstructive Surgery
Venous Thromboembolism · Deep Venous Thrombosis · Pulmonary Embolus
Primary: Avoidance of Under-anticoagulation (Peak aFXa <0.2 IU/mL) — 76.6; 79.9 percentage of participants
Phase 4 N=94 Study Of Tranexamic Acid For The Reduction Of Blood Loss In Patients Undergoing Major Abdominal Surgery
Biliary Tract Surgical Procedures · Pancreaticoduodenectomy · Esophagectomy
Primary: Post-operative Blood Loss — 394.3; 494.3 milliliter (mL) — p=0.460
N/A N=66 Heparin Dose and Post Operative Bleeding in Cardiopulmonary Bypass Patients
Coronary Artery Disease
Primary: Chest Tube Losses — 726; 781 millilters — p=<0.1
N/A N=100 The Effect of the Hemobag® Ultrafiltration System on Blood Conservation and Coagulation After Cardiopulmonary Bypass
Blood Coagulation Disorders
Primary: Amount of Chest Catheter Drainage 24 Hours Postoperatively — 766; 626 mL
N/A N=33 Intraoperative Bleeding During Endoscopic Sinus Surgery
Blood Loss
Primary: Estimated Blood Loss — 78.5; 80.3 mL/h — p=0.937
N/A N=106 Accuracy of Blood Loss Estimation After Vaginal Delivery
Postpartum Hemorrhage
Primary: Difference in Actual Blood Volume and Estimated Blood Volume in Milliliters. — -20.8; -41.7; -53.5; -96.0 milliliters — p=<0.05
Phase 4 N=18 Rectal Misoprostol as a Hemostatic Agent During Abdominal Myomectomy
Myomectomy; Surgical Blood Loss
Primary: Surgical Blood Loss — 761; 691 ml
N/A N=242 Validating a New Method to Assess Estimated Blood Loss in the Obstetric Population
Pregnancy Complications
Primary: Clinical Estimated Blood Loss (EBL) Between Cases and Controls Using Clinical Estimate Versus Device Assessment — 800; 800 milliLiters
N/A N=10 Blood Loss at the Time of First Trimester Surgical Abortion in Anticoagulated Women
Blood Loss
Primary: Volume of Intraoperative Blood Loss — 91.5; 52.2 milliliters
N/A N=234 The SURGICEL® Powder Mild or Moderate Parenchymal or Soft Tissue Intraoperative Bleeding (China Study)
Hemorrhage
Primary: Hemostatic Success at 5 Minutes — 109; 103 Participants — p=<0.0001
Phase 4 N=196 The Use of FLOSEAL to Reduce Bleeding in Total Knee Replacement Surgery
Blood Loss
Primary: Change in Hemoglobin on Day 0 Compared to Preoperatively — -1.277; -1.241 g/dL
N/A N=30 Protamine in Cardiac Surgery and Haemostasis
Bleeding · Hemorrhage
Primary: INTEM HEPTEM and FIBTEM Test of the ROTEM Coagulation Analyzer — 98; 117; 178; 253 seconds
Phase 3 N=57 Does Plasma Reduce Bleeding in Patients Undergoing Invasive Procedures
Blood Coagulation Disorders · Hemorrhage
Primary: Change in Hemoglobin Level — -0.6; -0.4 g/dL
Phase 4 N=58 Comparison of the Effects of Cervical Vasopressin Versus no Premedication on Blood Loss During Vaginal Hysterectomy: A Randomized, Placebo Controlled Trial
Blood Loss During Vaginal Hysterectomy
Primary: Intra-operative Blood Loss During Vaginal Hysterectomy
Phase 2 N=33 A Study Evaluating the Safety and Preliminary Efficacy of sFilm-FS in Controlling Parenchymal Bleeding During Elective Hepatic Surgery
Hemostasis · General Surgery
Primary: To Evaluate the Safety of sFilm-FS Versus an Active-comparator (TACHOSIL®) When Used as Adjunct to Conventional Hemostatic Techniques During Elective Surgery Through…
Phase 2 N=276 A Dose-ranging Safety and Efficacy Study of Ecallantide to Reduce Surgical Blood Loss Volume
Bloodloss · Surgical Procedures, Operative
Primary: Cumulative Volume of Packed Red Blood Cells Transfused at 12 Hours Post Surgery — 401.9; 383.1; 410.3; 377.6 mL — p=0.474
Phase 3 N=110 Tranexamic Acid for Prevention of Hemorrhage in Cesarean Delivery
Post Partum Hemorrhage · Fibrinolysis; Hemorrhage · Blood Loss
Primary: Blood Volume Loss — 2274; 2407 milliliters
Phase 2 N=100 The Effect of Tranexamic Acid on Postpartum Hemorrhage During and After Cesarean Delivery
Hemorrhage
Primary: The Amount of Hemorrhage During Cesarean Delivery and Within 2 Hours Afterward — 260; 380 ml
Phase 2 N=21 Tranexamic Acid Dosing for Major Joint Replacement Surgery
Arthroplasty, Replacement, Knee · Arthroplasty, Replacement, Hip
Primary: Blood Plasma TXA Concentration - Total Body Clearance — 58.0; 116 mL/min
N/A N=76 TXA Study in Major Oncologic Surgery
Tranexamic Acid · Cancer · Major Surgery
Primary: Number of Participants Who Required Transfusion — 8; 5 Participants